Generic drug business Impax Laboratories Inc. reported a 66 percent drop in revenue in the first quarter -- sales fell to $108.7 million from $323.3 million a year earlier.
Hayward-based Impax (NASDAQ: IPXL) blamed the $214 million drop in revenue on the success a year ago of the launch of a new product, Flomax, and also on “our continuing inability and frustration in obtaining sufficient generic Adderall XR product.”
No comments:
Post a Comment